233 related articles for article (PubMed ID: 30274040)
1. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery.
Miranda MS; Rodrigues MT; Domingues RMA; Torrado E; Reis RL; Pedrosa J; Gomes ME
Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():1090-1103. PubMed ID: 30274040
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary drug delivery systems for tuberculosis treatment.
Pham DD; Fattal E; Tsapis N
Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
[TBL] [Abstract][Full Text] [Related]
3. Development of Inhalable Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Microparticulate System for Antituberculosis Drug Delivery.
Miranda MS; Rodrigues MT; Domingues RMA; Costa RR; Paz E; RodrÃguez-Abreu C; Freitas P; Almeida BG; Carvalho MA; Gonçalves C; Ferreira CM; Torrado E; Reis RL; Pedrosa J; Gomes ME
Adv Healthc Mater; 2018 Aug; 7(15):e1800124. PubMed ID: 29797461
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
[TBL] [Abstract][Full Text] [Related]
5. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
6. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.
Sharma R; Saxena D; Dwivedi AK; Misra A
Pharm Res; 2001 Oct; 18(10):1405-10. PubMed ID: 11697465
[TBL] [Abstract][Full Text] [Related]
7. Dry powder inhalers of antitubercular drugs.
Nainwal N; Sharma Y; Jakhmola V
Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
Hanif SN; Garcia-Contreras L
Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
Mehta P; Bothiraja C; Kadam S; Pawar A
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
[TBL] [Abstract][Full Text] [Related]
11. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis.
Sharma A; Vaghasiya K; Gupta P; Singh AK; Gupta UD; Verma RK
J Control Release; 2020 Aug; 324():17-33. PubMed ID: 32418903
[TBL] [Abstract][Full Text] [Related]
12. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
13. Particulate pulmonary delivery systems containing anti-tuberculosis agents.
Gupta A; Pandya SM; Mohammad I; Agrawal AK; Mohan M; Misra A
Crit Rev Ther Drug Carrier Syst; 2013; 30(4):277-91. PubMed ID: 23662603
[TBL] [Abstract][Full Text] [Related]
14. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
15. Antitubercular inhaled therapy: opportunities, progress and challenges.
Pandey R; Khuller GK
J Antimicrob Chemother; 2005 Apr; 55(4):430-5. PubMed ID: 15761077
[TBL] [Abstract][Full Text] [Related]
16. [Development of Inhalable Dry Powder Formulations Loaded with Nanoparticles Maintaining Their Original Physical Properties and Functions].
Okuda T
Yakugaku Zasshi; 2017; 137(11):1339-1348. PubMed ID: 29093369
[TBL] [Abstract][Full Text] [Related]
17. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
Patil TS; Deshpande AS; Deshpande S; Shende P
J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Das Gupta U; Gupta P; Rath G; Goyal AK
Artif Cells Nanomed Biotechnol; 2016; 44(1):182-7. PubMed ID: 24992699
[TBL] [Abstract][Full Text] [Related]
19. Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs.
Ramachandran S; Prakash P; Mohtar N; Kumar KS; Parumasivam T
Pharm Dev Technol; 2023 Dec; 28(10):978-991. PubMed ID: 37937865
[TBL] [Abstract][Full Text] [Related]
20. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
